Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Informacje na temat projektu

ECRC

Identyfikator umowy o grant: 857934

DOI 10.3030/857934

Projekt został zamknięty

Data podpisania przez KE 16 Lipca 2019

Data rozpoczęcia 1 Stycznia 2019

Data zakończenia 29 Lutego 2024

Finansowanie w ramach

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Koszt całkowity € 51 428 572,00

Wkład UE € 36 000 000,00

Koordynowany przez

COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS
Norway

Rezultaty

Documents, reports (10)

SAC minutes

Summary of Scientific Advisory Committee meetings

Budget templates

Budget templates for awardees to complete

List of communication activities conducted, period 2

List of main communication activities conducted, period 2

List of communication activities conducted, period 4

List of main communication activities conducted, period 4

Project description template

CEPI's project description template for awardees

List of communication activities conducted, period 3

List of main communication activities conducted period 3

3rd periodic report to the EC

3rd periodic report to the EC containing deliverables

2nd periodic report to the EC

2nd periodic report to the EC , containing deliverables for given period

Opening of call online

Validation of the call being opened and made public

Call text

Call text published on the internet provided to the EC

Publikacje

Peer reviewed articles (5)

Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes

Autorzy: Corey L. Campbell, Trey K. Snell, Susi Bennett, John H. Wyckoff III, Darragh Heaslip, Jordan Flatt, Emma K. Harris, Daniel A. Hartman, Elena Lian, Brian H. Bird, Mark D. Stenglein, Richard A. Bowen, Rebekah C. Kading
Opublikowane w: WILEY ONLINE LIBRARY, Numer Volume 69, Numer 5, 2022, Strona(/y) Pages 2621-2633, ISSN 0000-0000
Wydawca: WILEY ONLINE LIBRARY
DOI: 10.1111/tbed.14415

Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera

Autorzy: Pierre Roques, Andrea Fritzer, Nathalie Dereuddre-Bosquet, Nina Wressnigg, Romana Hochreiter, Laetitia Bossevot, Quentin Pascal, Fabienne Guehenneux, Annegret Bitzer, Irena Corbic Ramljak, Roger Le Grand, Urban Lundberg, Andreas Meinke
Opublikowane w: JCI Insight, Numer Volume 7, Numer14, 2022, ISSN 2379-3708
Wydawca: JCI Insight
DOI: 10.1172/jci.insight.160173

Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo

Autorzy: Watson-Jones D, Kavunga-Membo H, Grais RF, Ahuka S, Roberts N, Edmunds WJ, Choi EM, Roberts CH, Edwards T, Camacho A, Lees S, Leyssen M, Spiessens B, Luhn K, Douoguih M, Hatchett R, Bausch DG, Muyembe JJ.
Opublikowane w: BMJ Open, Numer 2022, 2022, Strona(/y) 12, ISSN 2044-6055
Wydawca: BMJ Publishing Group
DOI: 10.1136/bmjopen-2021-055596

Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial

Autorzy: Nina Wressnigg, Romana Hochreiter, Oliver Zoihsl, Andrea Fritzer, Nicole Bézay, Anton Klingler, Karen Lingnau, Martina Schneider, Urban Lundberg, Andreas Meinke, Julian Larcher-Senn, Irena Čorbic-Ramljak, Susanne Eder-Lingelbach, Katrin Dubischar, Wolfgang Bender.
Opublikowane w: The Lancet, Numer Volume 20, Numer 10, 2020, ISSN 0140-6736
Wydawca: The Lancet Publishing Group
DOI: 10.1016/s1473-3099(20)30238-3

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial

Autorzy: Martina Schneider, Marivic Narciso-Abraham, Sandra Hadl, Robert McMahon, Sebastian Toepfer, Ulrike Fuchs, Romana Hochreiter, Annegret Bitzer, Karin Kosulin, Julian Larcher-Senn, Robert Mader, Katrin Dubischar, Oliver Zoihsl, Juan-Carlos Jaramillo, Susanne Eder-Lingelbach, Vera Buerger, Nina Wressnigg.
Opublikowane w: The Lancet, Numer VOLUME 401, ISSUE 10394, 2023, ISSN 0140-6736
Wydawca: The Lancet Publishing Group
DOI: 10.1016/s0140-6736(23)00641-4